GS GmbH Signs Technology License Agreement to Integrate Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) into Defibrillators and Patient Monitoring Systems
IRVINE, Calif. and KAUFERING, Germany, Aug. 20 Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, and GS Elektromedizinische Gerate G. Stemple GmbH, a German developer and manufacturer of innovative medical equipment for the Emergency Medical Services (EMS), today jointly announced a worldwide technology licensing agreement to integrate Masimo Rainbow SET Pulse CO-Oximetry into corpuls(R) patient monitoring modules. The agreement enables GS GmbH to expand the vital signs and noninvasive measurement capabilities of its defibrillators and patient monitoring systems to help EMS professionals detect and treat life-threatening conditions earlier.
The breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry allow for continuous monitoring of hemoglobin, carbon monoxide, methemoglobin, PVI for fluid responsiveness, perfusion index, and measure-through motion pulse oximetry. With Masimo Rainbow SET, the ability to detect internal bleeding, carbon monoxide poisoning, methemoglobinemia, fluid responsiveness, perfusion, saturation, and pulse rate quickly, easily and continuously can help save lives and improve patient outcomes.
According to Klaus Stemple, General Manager of GS GmbH, the key to "developing better lifesaving support solutions and techniques is to stay ahead of the mainstream. Our corpuls products are innovative leaders in the defibrillator market and the integration of Masimo Rainbow SET Pulse CO-Oximetry measurements is another consistent step in the design and manufacture state-of-the-art defibrillator/monitoring-systems that spearhead the industry in patient monitoring performance. The combination of corpuls and Masimo Rainbow SET creates a unique defibrillator solution for EMS professionals looking to leverage additional vital parameters to more thoroughly assess a patient's physiological status and make better clinical and treatment decisions."
The corpuls3--a unique 3-in-1 modular defibrillator system combining three components including: a compact patient box, a large monitoring unit, and a defibrillator/pacer unit -- will be one of the first products to feature Masimo Rainbow SET Pulse CO-Oximetry capabilities. The Masimo Rainbow SET measurement option will be available in mid-2010.
Masimo Founder and CEO, Joe E. Kiani, stated, "GS GmbH was one of the first European equipment manufacturers to license Masimo SET pulse oximetry technology over 10 years ago. Today, they are still a market leader in providing innovative EMS solutions throughout Europe and, with this technology license agreement, will further expand the availability of Masimo Rainbow SET Pulse CO-Oximetry to the benefit of patients and EMS professionals alike."
About GS GmbH
GS Elektromedizinische Gerate G. Stemple GmbH is a German company and internationally-operated business specializing in the development and manufacture of innovative high-end medical devices for emergency medical services and intensive care for over 25 years. The corpuls(R) defibrillators and patient monitoring systems are robust, reliable and durable devices designed for use in the first aid treatment of people suffering from sudden cardiac arrest. Additional information about corpuls and its products may be found at www.corpuls.com.
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the timing and commercial availability of corpuls3 featuring Masimo Rainbow SET Pulse CO-Oximetry technology, risks related to our belief that Masimo Rainbow SET will provide sufficient sensitivity and specificity to detect physiological abnormalities in real-time, enabling EMS professionals to detect and identify potentially life-threatening conditions earlier and make better clinical and treatment decisions for their patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation. Corpuls and Corpuls3 are trademarks or registered trademarks of GS Elektromedizinische Gerate G. Stemple GmbH.
Media Contacts: Dana Banks Masimo Corporation +1 (949) 297-7348
SOURCE Masimo Corporation
You May Also Like